Details of the Drug

General Information of Drug (ID: DM4O90W)

Drug Name

Insulin-lispro

Synonyms

WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1], [2], [3]

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
4

Molecular Weight

5814

Topological Polar Surface Area

Not Available

Rotatable Bond Count

185

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Bioavailability: The bioavailability of drug is 55-77% [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [5]
Metabolism: The drug is metabolized via a receptor-mediated process [4]
Vd: The volume of distribution (Vd) of drug is 1.55 L/kg [6]

Chemical Identifiers

Formula: C257H389N65O77S6
IUPAC Name: (4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
Canonical SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
InChI: InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
InChIKey: WNRQPCUGRUFHED-DETKDSODSA-N

Cross-matching ID

PubChem CID: 16132438
CAS Number: 133107-64-9
TTD ID: D0L6JE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin receptor (INSR)	TTCBFJO	INSR_HUMAN	Binder	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Insulin receptor (INSR)	DTT	INSR	1.03E-05	0.26	0.66

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Insulin-lispro (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oxandrolone	DMU9MYJ	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Oxandrolone.	Alcoholic liver disease [DB94]	[15]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Oxymetholone.	Aplastic anaemia [3A70]	[15]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Linezolid	DMGFPU2	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Linezolid.	Bacterial infection [1A00-1C4Z]	[15]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[15]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[15]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sertraline.	Depression [6A70-6A7Z]	[15]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fluoxetine.	Depression [6A70-6A7Z]	[15]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Vilazodone.	Depression [6A70-6A7Z]	[16]
Paroxetine	DM5PVQE	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Paroxetine.	Depression [6A70-6A7Z]	[15]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Selegiline.	Depression [6A70-6A7Z]	[15]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Vortioxetine.	Depression [6A70-6A7Z]	[15]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Escitalopram.	Depression [6A70-6A7Z]	[15]
Tranylcypromine	DMGB5RE	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Tranylcypromine.	Depression [6A70-6A7Z]	[15]
Phenelzine	DMHIDUE	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Phenelzine.	Depression [6A70-6A7Z]	[15]
Fluvoxamine	DMQTJSX	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fluvoxamine.	Depression [6A70-6A7Z]	[15]
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and PMID28454500-Compound-96.	Discovery agent [N.A.]	[15]
Citalopram derivative 1	DMITX1G	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Citalopram derivative 1.	Discovery agent [N.A.]	[15]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and PMID28870136-Compound-49.	Discovery agent [N.A.]	[15]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Ramipril	DM2R68E	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Ramipril.	Heart failure [BD10-BD1Z]	[15]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[15]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[15]
Clofibrate	DMPC1J7	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Clofibrate.	Hyper-lipoproteinaemia [5C80]	[15]
Eprosartan	DM07K2I	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Eprosartan.	Hypertension [BA00-BA04]	[15]
Moexipril	DM26E4B	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Moexipril.	Hypertension [BA00-BA04]	[15]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Captopril.	Hypertension [BA00-BA04]	[15]
Trandolapril	DM4L6EU	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Trandolapril.	Hypertension [BA00-BA04]	[15]
Losartan	DM72JXH	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Losartan.	Hypertension [BA00-BA04]	[15]
Fosinopril	DM9NJ52	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Fosinopril.	Hypertension [BA00-BA04]	[15]
TAK-491	DMCF6SX	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and TAK-491.	Hypertension [BA00-BA04]	[15]
Benazepril	DMH1M9B	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Benazepril.	Hypertension [BA00-BA04]	[15]
Enalapril	DMNFUZR	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Enalapril.	Hypertension [BA00-BA04]	[15]
Perindopril	DMOPZDT	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Perindopril.	Hypertension [BA00-BA04]	[15]
Quinapril	DMR8H31	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Quinapril.	Hypertension [BA00-BA04]	[15]
Valsartan	DMREUQ6	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Valsartan.	Hypertension [BA00-BA04]	[15]
Telmisartan	DMS3GX2	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Telmisartan.	Hypertension [BA00-BA04]	[15]
Irbesartan	DMTP1DC	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Irbesartan.	Hypertension [BA00-BA04]	[15]
Lisinopril	DMUOK4C	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Lisinopril.	Hypertension [BA00-BA04]	[15]
Testosterone	DM7HUNW	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Testosterone.	Low bone mass disorder [FB83]	[15]
Chloroquine	DMSI5CB	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Chloroquine.	Malaria [1F40-1F45]	[15]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Hydroxychloroquine.	Malaria [1F40-1F45]	[15]
Quinine	DMSWYF5	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Quinine.	Malaria [1F40-1F45]	[15]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulphadoxine.	Malaria [1F40-1F45]	[15]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[15]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Dextropropoxyphene.	Pain [MG30-MG3Z]	[16]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Aspirin.	Pain [MG30-MG3Z]	[16]
Diflunisal	DM7EN8I	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Diflunisal.	Pain [MG30-MG3Z]	[15]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Safinamide.	Parkinsonism [8A00]	[15]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Rasagiline.	Parkinsonism [8A00]	[15]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[15]
Sulfadiazine	DMTW3R8	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulfadiazine.	Rheumatic fever [1B40]	[16]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Salsalate.	Rheumatoid arthritis [FA20]	[15]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulfasalazine.	Rheumatoid arthritis [FA20]	[15]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[16]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[15]
Sulfamethizole	DMGCHDS	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulfamethizole.	Urinary tract infection [GC08]	[15]
Sulfisoxazole	DMXLT8C	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Sulfisoxazole.	Urinary tract infection [GC08]	[15]
Disopyramide	DM5SYZP	Moderate	Increased risk of hypoglycemia by the combination of Insulin-lispro and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[15]
-----------


⏷ Show the Full List of 60 DDI Information of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002887)
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
8	New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
9	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
10	Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
11	Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
12	Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
14	Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144.
15	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
16	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]